After initiation of insulin therapy, approximately 50–60% of patients with newly diagnosed T1D experience a temporary phase known as partial remission, characterized by a resurgence of residual β-cell insulin secretion. The gene discussed is INS; the disease is type 1 diabetes mellitus.